OmniaBio: Streamlining Your Path to Market: Leveraging the Latest CAR T Cell Technologies and Enabling Tools
Friday, May 31, 2024 05:00 PM - 06:00 PM
Room 217-219
Chair
CAR T cell therapies have revolutionized treatment outcomes for a variety of cancers, offering promising results and cures for patients. However, the key to a therapeutic developer’s success often relies in their ability to rapidly advance through clinical development to market with a robust, scalable, and cost-effective manufacturing process. OmniaBio, a technology-driven, full-service contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, built upon CCRM’s innovation ecosystem model. During this session, we will introduce OmniaBio’s CAR T therapy platform, adaptable to meet a variety of workflows, streamlining the clinical development journey. We will also engage an expert panel on what is required for manufacturing intensification for the next wave of CAR T commercialization.
Session Objectives
- Neil Blackburn, Senior Director, Process Development and Analytics, OmniaBio Inc., Canada
- Tim Moore, Chief Technical Officer, Allogene, USA
- Aaron Dulgar-Tulloch, PhD, Chief Technology Officer, Cytiva Genomic Medicine, Canada
- David Shaw, PhD, Senior Director, Head of Cell Therapy Engineering and Process Development, Pharma Technical Cell and Gene Therapy, Genentech, United States
CAR T cell therapies have revolutionized treatment outcomes for a variety of cancers, offering promising results and cures for patients. However, the key to a therapeutic developer’s success often relies in their ability to rapidly advance through clinical development to market with a robust, scalable, and cost-effective manufacturing process. OmniaBio, a technology-driven, full-service contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, built upon CCRM’s innovation ecosystem model. During this session, we will introduce OmniaBio’s CAR T therapy platform, adaptable to meet a variety of workflows, streamlining the clinical development journey. We will also engage an expert panel on what is required for manufacturing intensification for the next wave of CAR T commercialization.
Session Objectives
- Discuss commercialization challenges for CAR T therapies from manufacture through final product release and delivery to patients
- Introduce OmniaBio’s scalable, robust CAR T cell therapy platform and its ability to accommodate various cell types and unit operations
- Gain insights into next-generation industrialization strategies for intensifying CAR T cell therapy manufacturing
- Learn how enabling tools and the right manufacturing strategy can streamline the path to clinic and market, while providing safe and reliable manufacturing of CAR T cell therapies
SPONSORED BY:
David Shaw
Senior Director, Head of Cell Therapy Engineering and Process Development
Genentech, Inc.
Speaker
Senior Director, Head of Cell Therapy Engineering and Process Development
Genentech, Inc.
Speaker